Chamber holder for immobilized immunoadsorbent

ABSTRACT

An immobilized immunoadsorbent for use in immunoassay and radioimmunoassay procedures includes, in a preferred form, a mass of superficially porous refractory particles having a water insoluble polymer, such as dextran, bonded thereto. The polymer in turn has bonded to it, by covalent bonds, antibodies capable of binding a specific antigen thereto and stoichiometrically releasing the bound antigen by the use of a rinsing solution which does not adversely affect the binding of the antibody to the polymer. Preferably, each of the porous particles includes an impervious core which has joined thereto sufficient layers of microparticles to form an outer porous coating on the core. Methods of forming such an immunoadsorbent and for using the same and structure for supporting the same.

This is a division of application Ser. No. 565,848, filed Apr. 7, 1975,and now U.S. Pat. No. 4,095,685.

RELATED APPLICATIONS

Reference is made to application Ser. No. 342,513, filed Mar. 19, 1973,assigned to the same assignee, and now U.S. Pat. No. 3,896,217.

BACKGROUND OF THE INVENTION

This invention relates to immunoadsorbents and more particularly to animproved immunoadsorbent for use in immunoassay procedures such asradioimmunoassay wherein the immunoadsorbent may be used for repeatedassays.

STATE OF THE ART

Radioimmunoassay is an analytical technique which depends upon thecompetition (affinity) of antigen for antigen-binding sites on antibodymolecules. In practice, standard curves are constructed from datagathered from a plurality of samples each containing (a) the same knownconcentration of labelled antigen, and (b) various, but known,concentrations of unlabelled antigen. Antigens are labelled with aradioactive isotope tracer. The mixture is incubated in contact with anantibody, the free antigen is separated from the antibody and theantigen bound thereto, and then, by use of a suitable detector, such asa gamma or beta radiation detector, the percent of either the bound orfree labelled antigen or both is determined. This procedure is repeatedfor a number of samples containing various known concentrations ofunlabelled antigens and the results plotted. The percent of bound tracerantigens is plotted as a function of the antigen concentration.Typically, as the total antigen concentration increases the relativeamount of the tracer antigen bound to the antibody decreases. After thestandard graph is prepared, it is thereafter used to determine theconcentration of antigen in samples undergoing analysis.

In actual analysis, the sample in which the concentration of antigen isto be determined is mixed with a known amount of tracer antigen. Tracerantigen is the same antigen known to be in the sample but which has beenlabelled with a suitable radioactive isotope. The sample with tracer isthen incubated in contact with the antibody. Thereafter, it may becounted in a suitable detector which counts the free antigen remainingin the sample. The antigen bound to the antibody or immunoadsorbent mayalso be similarly counted. Then, from the standard curve, theconcentration of antigen in the original sample is determined.Afterwards, the antibody or immunoadsorbent mass is discarded.

In order to detect the percentage of antigen that is bound to theantibody (bound antigen) and/or the percentage that remains free orunbound it is necessary to first separate the sample into a fractioncontaining bound antigen and one containing only free antigen. Onecommon method for doing this is to add a dextran coated charcoal to themixture. The dextran permits the unbound antigen, of lower molecularweight than the bound antigen, to pass through the dextran and thecharcoal adsorbs the free antigen. The charcoal with adsorbed freeantigen is then separated from the antibody (and bound antigen) bycentrifugation.

Another known procedure is to add to the mixture another antibody whichselectively precipitates the first antibody (with the bound antigen)thus leaving in solution only free antigen. Classification intoappropriate free and bound fractions is then effected by separating theprecipitate from the supernatant by centrifugation or other suitablemeans. Some workers have resorted to the technique of binding theantibody to the inner walls of a plastic vessel, filling the vessel withthe antigen bearing sample, allowing it to stand for an incubationperiod that typically ranges from 4 to 72 hours and then separating freeantigen from bound antigen by draining and rinsing the vessel leavingtherein only the antibody and bound antigen. A more recently developedtechnique is to prepare the immunoadsorbent by binding the antibodiesonto an insoluble cross-linked dextran. The immunoadsorbent and antigenbearing sample are incubated then the dextran with bound antigen isseparated from the solution by suitable means.

In all of the foregoing procedures, the percentage of labelled antigenin either or both the bound or free fractions is determined and thestandard curve used to determine the antigen concentration. Thereafter,the immunoadsorbent is discarded.

Although the foregoing radioimmunoassay techniques have proven to bevaluable tools and have gained widespread acceptance, they are still notall that are to be desired because the antibody (immunoadsorbent) isconsumed with each analysis hence must be discarded. Moreover, priorpractice is batch type and the several reagents are added to theantibody in test tubes in which the separate steps, such as incubation,rinsing and the like, are performed, thus resulting in a slow and costlyoperation.

The above-identified application describes a substantial improvement inimmunoassay procedures in that the same immunoadsorbent may be usedrepeatedly for many assays by releasing from the immunoadsorbent theantigen which is bound to the antibody mass, the latter immobilized onthe substrate; i.e. selectively and stoichiometrically releasing all ofthe antigen on the immunoadsorbent after the assay is completed. It isto be reusable immunoadsorbent that the present invention is directed.

DESCRIPTION OF THE PRIOR ART

It is known from the literature that antibodies may be isolated by useof immunologic adsorbents, the technique being useful for isolation andpurification of antibodies rather than quantitative determinationthereof, see Campbell et al, Proc. Nat'l. Acad. Sci. U.S. 37 (1951) 575.

The use of an antibody coupled to an insoluble polymer for extractingspecific antigens for purposes of isolating and purifying the same isdescribed in Weetall et al, Biochem. Biophys. Acta. 107 (1965) 150-152.

Porous glass has been described as a substrate for immobilizing enzymes,see Weetall, Biochem. Biophys. Acta. 212 (1970) 1-7. There, glass wastreated with gammaaminopropyltriethoxysilane and the isothiocyanatederivative was prepared by treatment with thiophosgene. The enzyme wascoupled to the isothiocyanate derivative. Also described in thepreparation of an arylamine derivative by the reaction of alkylamineglass with P-nitrobenzoly chloride followed by use of sodium dithionateto reduce the nitro groups. The arylamine glass was then diazotized andthe enzyme coupled thereto.

Weetall, in Biochem. J. (1970) 117, 257-261 also describes the use ofantibodies bound to porous glass through a silane coupling agent, theimmunoadsorbent being used to isolate and purify specific antigens. Thedata given, however, shows that the reused column, in which the antigenwas eluted from the immobilized antibody immunoadsorbent was quiteerratic in performance since the recovery of released antigen variedfrom 74% to 100%. See also U.S. Pat. No. 3,652,761 of Mar. 28, 1972.While useful as an isolation system, the described system hasconsiderable objections from the standpoint of a useable tool inquantitative analysis in which there must be substantiallystoichiometric release of the antigen.

U.S. Pat. No. 3,555,143 of Jan. 12, 1971, relates to radioimmunoassayprocedures in which an immobilized immunoadsorbent is used only once andthen discarded. The immunoadsorbent is a dextran (Sephadix G 25,superfine) cross-linked with glycerine ether bridges and substitutedwith p-nitrophenoxy-hydroxy-propyl ether groups. The nitro groups arereduced to amine groups using sodium dithionite. The Sephadexsubstituted with p-amino-phenoxy-hydroxy-propyl groups was then treatedwith thiophosgene to form Sephadex substituted withp-isothiocyanate-phenoxy-hydroxypropyl groups, the antibody being boundto the latter substituted product.

A reaction widely used to insolubilize a protein involves a covalentbinding of the protein to a cyanogen bromide activated cellulose matrix.The mechanism of such activation is set forth in Bartling et al,Biotechnology and Bioengineering, Vol XIV (1972) 1039-1044.

U.S. Pat. Nos. 3,502,888 of July 13, 1971; 3,639,559 of Feb. 1, 1972,and 3,720,760 of Mar. 13, 1972 are also of interest.

Where an immobilized immunoadsorbent is to be used only once anddiscarded, the long term properties of the substrate are not of majorconsequence. Thus, materials such as Sephadex (dextran) or Sepharose(beaded agarose product) operate satisfactorily as substrates forantibodies bound thereto as described in U.S. Pat. No. 3,555,143, supra.Where the immunoadsorbent is to be used repeatedly, as described in theabove-identified application Ser. No. 342,513, certain problems arise.

One of the objections is the tendency of Sephadex and Sepharose typeproducts to dehydrate, that is, the gel collapses and packs to such anextent that flow through the mass is substantially impeded and theavailability of antibody for binding antigen is altered, thus affectingthe reproducibility and stability of the immunoadsorbent for repeateduse.

Glass and other solid inorganic materials offer a desirable alternativebecause they can be formed into beads to provide better flow and easierpacking into a column type arrangement. Such materials do not collapseand are not subject to dehydration during periods of extended use. Whilea desirable alternate, glass type products also suffer fromdisadvantages. One of the problems is obtaining a sufficient binding ofthe antibody to the substrate. Either an insufficient initial bindingtakes place to provide the activity needed for a quantitative analysistool, or the activity changes over the life of the immunoadsorbent byundesirable release of antibodies.

Where the glass is highly porous, as that used by the Weetall referencescited, there is so much active glass surface area that ample binding ofthe antibody takes place but nonspecific binding of the antigen alsotakes place. Thus, the antigen bound to the glass is not releasedcompletely. That is, rather than having a stoichiometric release, foreach use thereof, as is needed for quantitative analysis, the releasecharacteristics are variable and unpredictable. This is confirmed by theWeetall data. Since such glass is usually 96% air or void space, thereis considerable active surface area of the glass, not occupied byantibody which serves as an antigen binding site.

Another difficulty with highly porous glass products is that there aremultiple crevices in the pores which result in trapping in the crevicesand slow release because of the slow diffusion in the crevices. Where afast response is needed, as for example in automated equipment, thediffusion of the reactants is a rate limiting step and, as is wellknown, diffusion may be a relatively slow process. Thus, even if notbound to the substrate, the diffusion of the antigen is relatively slowand thus, for the purpose of rapid automated assay equipment, theantigen is effectively bound rather than being rapidly andstoichiometrically released.

Superficially porous supports are known for use in chromatography, seefor example U.S. Pat. No. 3,505,785 of Apr. 14, 1970 which describes aproduct commercially available from E. I. du Pont de Nemours and Co.under the trademark "Zipax". These support beads for use aschromatographic column packing consists of a plurality of discretemacroparticles with impervious cores and having irreversibly joinedthereto a coating of a series of sequentially adsorbed-like monolayersof like colloidal microparticles. Thus, spherical glass microbeads ofabout 30 microns diameter include an outer porous surface crust which isabout one micron thick. Such a material, if used as a substrate offerssubstantial surface area for the desired activity, but the substratemust be properly prepared to assure the proper quick response as well asstoichiometric release.

Thus, the provision of a reusable immunoadsorbent and whichstoichiometrically releases the antigen for each assay is quitedesirable. Where that immunoadsorbent is also substantially free ofdehydration and packs such that the flow quality through the mass is ofdesirable character over the useful life of the immunoadsorbent, asubstantially improved reuseable immobilized immunoadsorbent isprovided.

SUMMARY OF THE INVENTION

In accordance with this invention, an improved immobilizedimmunoadsorbent is provided for use and reuse in radioimmunoassayprocedures. The substrate or basic matrix is stable against dehydrationand collapse and is in the form of a mass of solid particles each havingan outer surface of high surface area. A typical such substrate iscomposed of superficially porous refractory particles, each of whichincludes an impervious core having joined thereto sufficient layers ofmicroparticles to form an outer porous coating on the core to provide ahigh surface area.

To the substrate is bonded a water insoluble polymer material. Thepolymer may be bonded by treating the substrate to form an aminoalkylsilane derivative thereof followed by treatment to form anisothioayanoalkylsilane derivative to which the polymer is bound.Typical of the useful polymer materials is dextran.

The dextran operates as a barrier to cover the active sites on thesubstrate to which antigen may be bound in such a way as to interferewith subsequent assays. Since the immunoadsorbent of this invention isused and reused, by use of an eluting medium which separates the antigenfrom the bound antibodies, the release of any antigen which may be boundto the substrate creates errors in subsequent assays. The error arisesbecause of the unpredictable and unknown amount retained or released.Thus, the polymer affectively operates as a barrier to prevent thesubstrate from binding antigen.

The polymer is then activated to bind antibody through a covalent bondby treatment with cyanogen bromide, the mechanism of the reaction beingas described in Bartling et al, supra.

The resultant immobilized immunoadsorbant is then placed in a chamberholder of a unique structure for use on automated equipment as describedin the above application Ser. No. 342,513.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a view in perspective with a portion thereof broken away andin section to illustrate diagrammatically the substrate useable inaccordance with this invention; and

FIG. 2 is a view in section of a chamber holder in accordance with thisinvention.

DETAILED DESCRIPTION OF THE INVENTION

The improved immobilized immunoadsorbent of the present invention isintended for use principally in radioimmunoassay procedures.

Typical of the materials which may be quantitatively determined by thesystem of the present invention are the following: estriol, digoxin,digitoxin, testosterone, estradiol, aldosterone, progesterone, cortisol,11-desoxycortiosterone, 11-desoxycortisol, thyroid hormones such asthyroxin (T₄) triiodothyronine (T₃), polypeptides sudh as angiotensin,TSH (thyroid stimulating hormone), ACTH, GH (growth hormone), HP (humanplacento-lactogen), parathormone, calcitonin, insulin, glucagen,polypeptide proteins such as CEA (carcino embrionic antigen),alphafetoprotein, interferon, viruses such as Australia antigen,vitamins such as D and B₁₂ folic acid and drugs such as dilantin andbarbiturates, to mention only a few.

The antisera for the above antigens are known, as are the labelledantigens, available in the form of radioactive isotope labelledmaterials, usually in the form of the I¹²⁵ isotope or H³ isotope.

The immobilized immunoadsorbent of this invention includes a substratewith which the antibodies are relatively permanently associated. In use,an unlabelled antigen sample with a known concentration of labelledantigen is brought into contact with the immobilized immunoadsorbentdisposed in a chamber holder. When brought into contact, a portion ofthe mixture of labelled antigen and unlabelled antigen binds to thespecific antibody bound on the substrate. Thereafter, the unboundantigen or the bound antigen or both are counted and concentration ofthe unlabelled antigen is determined from standard data.

Thereafter, the immobilized immunoadsorbent is rinsed with anappropriate aqueous solution containing solvents such as methyl alcohol,isopropyl alcohol or ethyl alcohol as well as dimethyl formamide toeffect a stoichiometric release of the bound labelled and unlabelledantigen from the immobilized immunoadsorbent. The rinsing or elutingoperation effectively regenerates the immunoadsorbent for reuse, andthereafter, the same immunoadsorbent may be used again, repeatedly, forassays of that antigen as to which the immobilized antibody is specific,with washings, as described between each use.

Since the antigen material is flowed into a chamber supporting theimmunoadsorbent which is reused, the flow characteristic of thesubstrate should be such that contact is achieved between the supportedantibodies and antigen mixture. Moreover, the substrate must be of sucha type as not to interfere with release of the bound antigen whileretaining the bound antibody. Reproducibility, stability and speed aresome of the advantages of the improved method, and thus the substratemust be such that sufficient activity may be obtained in terms of boundantibody with available antigen binding sites. It is preferred,therefore, that the substrate be particulate, and spherical i.e. formedof a mass of discrete particles since this enhances the desirableflow-through character of not only the sample mixture of labelled andunlabelled antigen, but of the rinse or eluting medium as well.

Particulate materials capable of providing the needed antibody activelyunknown, e.g. Sephadex, Sepharose, porous glass and the like. Materialssuch as Sephadex and Sepharose are gel type materials and over periodsof extended use, tend to dehydrate resulting in collapse with resultingpacking which impedes the flow. Materials such as porous glass are soactive that antigen is bound to the glass and not released.

Thus, an important aspect of this invention is the formation of abarrier coating over a particulate substrate, the barrier coatingoperating to provide, in effect, a mask which precludes the potentiallyactive sites on the substrate from irreversibly binding the antigens.The barrier also functions as an immobilized component of the substrateto which the antibodies may be attached. Since assays are conducted inaqueous and non-aqueous solvents, the barrier coating is preferablyinsoluble and not adversely affected by the solvents and solutions usedin the procedure. Water insoluble polymer materials such as dextran arepreferred in accordance with this invention.

The substrate itself is preferably a particulate material resistant todehydration and collapse. Rapid mass transfer at relatively high flowrates are a function of substrate geometry, and packing character in thechamber holder. A preferred substrate is a material having a controlledsurface porosity, superficially porous refractory particles made up ofdiscrete macroparticles with impervious non-porous cores, and havingjoined ther to a coating of a series of sequentially adsorbed likemonolayers of like inorganic microparticles.

Referring to FIG. 1, for purposes of illustration, the superficiallyporous refractory particle 10 which forms the substrate for theimmobilized immunoadsorbent includes a core 12 in the form of amacroparticle which is an impervious non-porous core. The core 12 isshown as spherical because this shape is preferred for packing purposes.The core, in the form of a sphere is of a diameter of between 5 and 500microns in diameter and composed of glass, although it may be of sands,ceramics, and the like.

The cores are preferably of uniform size i.e. all within about 50% ofthe average diameter. Affixed to the core 12 is a plurality of layers ofmicroparticles 14 which form an outer porous coating. The microparticlesmay range in size from 5 millimicrons to 1 micron, and the number oflayers may be between 2 and 30. The micro-particles may be amorphoussilica, alumina, thoria and the like.

As will be apparent, a substrate of material as described has arelatively high surface area due to the porous coating 15, but isrelatively free of pores in the core material. For beads of an overalldiameter of 30 microns, and a porous crust of one micron, a surface areaof between 0.8 to 1.0 m² /gram is obtained, with a packed bed density of1.5g/cc. The regular geometry, the stability against dehydration andcollapse, and the bulk renders the above material quite exceptional as asubstrate.

However, there is a tendency for such a material, if used in the formdescribed as a substrate directly for the antibody material, to containactive sites which tend to bind the antigen mixture or a componentthereof in a nonreleasable manner. This problem may be quiteobjectionable where the immobilized immunoadsorbent is reused, animportant objective in this invention. Since the accuracy and speed ofthe assay is, in part, related to the ability of the antibody to bindthe antigen and stoichiometrically release the same when rinsed, anyunreleased antigen adversely affects the accuracy of subsequent assay.While a background count could be taken, this is not entirelysatisfactory since the retention-release phenomena tends to benon-uniform and non-predictable.

By this invention, such a tendency is eliminated by the use of a barriercoating adhered to the substrate through a silane coupling agent, i.e.the polymer is bound directly to the outer surface portions of thesubstrate by silane linkages. The polymer is then activated by treatmentwith cyanogen bromide which covalently binds the protein (antibody) tothe polymer activated particulate substrate. The polymer coating notonly acts as a barrier, effectively to mask latent active sites on thesubstrate proper, but offers an active surface to which the antibody maybe covalently bound, a bond recognized as relatively strong.

In a typical procedure, in accordance with this invention, 12 grams ofparticulate substrate material (30 micron diameter superficially porousrafractory particles, as described supra) were added to a 500 ml flaskto which was added 20 ml (18.84 grams) of 3-aminopropyltriethoxysilaneand 180 ml of toluene. The mixture was refluxed for 22 hours to form theaminoalkylsilane derivative of the glass substrate. The derivative wasfiltered, washed with 200 ml of toluene while on the filter support, andair dried, followed by a second washing with 100 ml of chloroform and asecond air drying.

The isothiocyanoalkylsilane derivative was prepared by treating theprepared aminoalkylsilane glass derivative with 16.6 ml (25 grams) ofthiophosgene and 150 ml of chloroform. The reaction vessel was protectedfrom light and refluxed for 18 hours to form the described derivative,which was filtered, washed in chloroform, and air dried.

The result of the steps thus far was to prepare an "activated" substrateto which the water insoluble polymer may be bound.

In accordance with this invention it is preferred to use dextran of amolecular weight of 70,000, although other materials may be used.

Accordingly, two hundred ml of a 1% solution of dextran in 0.1 m sodiumbicarbonate, pH 9.0, were added to the "activated" substrate. Themixture was stirred for three hours, filtered, washed with 300 ml ofwater, washed with 100 ml of acetone and air dried to provide 11.6 gramsof polymer coated particulate substrate.

The remaining steps in the procedure involve activation of the polymercoated substrate and, optionally, the purification of the antibody, andbinding the antibody to the coated substrate, sometimes referred to asthe conjugation of the antibody to prepared substrate.

To activate the dextran, twenty grams of cyanogen bromide were dissolvedin 200 ml of water. Cyanogen bromide is quite toxic and thereforestandard safety precautions are taken. The dextran coated substrate wasadded (11.6 grams) and the mixture stirred. The pH was raised from 3.6to pH 10-11 using 23 ml of 6 N sodium hydroxide. The pH was maintainedbetween 10 and 11 by the addition of 6 N sodium hydroxide for twominutes. The activated dextran coated substrate was then washed with 400ml of water, 400 ml of 50%, on a volume basis, of water and acetone, 400ml of 25%, on a volume basis, of water and acetone and finally 400 ml ofacetone. The product was then air dried.

Treatment of the polymer coated substrate with cyanogen bromide resultsin reaction with adjacent hydroxyl groups on the polymer to form animidocarbonate which couples with the nucleophilic groups (amino) on theantibody to form the carbonic acid ester on hydrolysis. Rapid hydrolysisof the imidocarbonate in acid media results in formation of a cycliccarbonate which is not as efficient in binding as the imidocarbonate.Thus, care should be taken to avoid conditions promoting cycliccarbonate formation.

Simple purification of the antibody prior to conjugation may optionallybe conducted as follows: one ml of 18% sodium sulfate was added to 0.1ml of the antisera. The solution was vortexed and incubated for one hourto precipitate gamma globulins. The resulting mixture was thencentrifuged for five minutes at 1000 xg at room temperature followed bydecanting and discarding the supernatant. The pellet was suspended in 10ml of 18% sodium sulfate with addition of 0.10 ml of water. Theresulting mixture was then vortexed and centrifuged again. Thesupernatant is decanted while the pellet was dissolved in 0.8 ml of 0.1M sodium bicarbonate solution.

It is preferred in accordance with the present invention to conjugatethe antibody to the substrate while the latter is saturated with antigenas to which it is specific. The reason for this procedure is to obtainenhanced activity by protecting the active sites on the antibody duringthe conjugation procedure, thus, in effect assuring that the antibodywill assume a relation with the substrate which assures availability ofactive sites. In a sense, the binding of the active sites with antigenallows an orientation of the antibody which reduces masking of the sitesby the conjugation procedure.

Thus, a 0.5 ml aliquot of a 0.1 mg/ml solution of antigen, specific tothe antibody, was dissolved in an ethanol-water solution (2 partsethanol and 1 part water) and dried down in a test tube with nitrogengas. The purified antisera, dissolved in 0.8 ml of 0.1 M sodiumbicarbonate, or 0.1 ml of antisera in 0.8 ml of 0.1 M sodium bicarbonatewas added to the tube containing the dried antigen followed byincubation for one hour in a capped culture tube. Thereafter, 300 mg ofthe cyanogen activated polymer coated substrate were added to the tubecontaining the antibody solution and incubated for one to three days at4° C. while mixing. During the incubation period the conjugation takesplace with the antibody having its antigen binding sites protected bybound antigen.

After incubation, the suspension was centrifuged at 1000 xg for fiveminutes and the supernatant decanted and discarded. The pellet waswashed two times with 10 ml of 0.5 M sodium bicarbonate solution. Aftereach wash the suspension was centrifuged and the supernatant discarded.The antibody coated substrate was then washed two times with 10 ml of0.1 M acetate buffer, pH 4. The antibody coated substrate was thenwashed with 10 ml of 0.05 M phosphate buffer, pH 7.5, containing 0.05 Msodium chloride and 0.5% bovine serum albumin and 0.02% sodium azide asa preservative. The resulting product was then resuspended in 10 ml ofthe last wash solution and stored at 4° C.

The resultant product, prior to use in an assay, is rinsed with one ofthe solutions described to release the antigen bound to the immobilizedantibody. In storage, however, it is preferred that the antigen remainbound to the antibody.

It is possible, in accordance with this invention to conjugate theantibody, in a free state, to the substrate. This procedure involvesadmixing the antibody to the cyanogen activated polymer coated substratefollowed by incubation and post treatment as already described.

One aspect of the present invention involves the provision of a chamberholder for the immobilized immunoadsorbent. Referring to FIG. 2, thechamber holder 25 includes a supporting body 27 which is cylindrical inshape for ease of installation. Provided within the body 27 is a chamber30 which contains the immobilized immunoadsorbent matter 32, illustratedas particulate material. The immunoadsorbent is supported in the chamberby a porous plug 34 whose pore size is smaller than the particles makingup the immunoadsorbent. An outlet 36 is provided for exit of materialflowed through the chamber through an inlet 38. The plug 34 is pressfitted in the support body which may be of a plastic material such aspolypropylene or "DELRIN". By way of example, the chamber is 1/8 inch indiameter and 1/4 inch long while the plug is 1/8 inch by 1/8 inch 10micron pore size.

Positioned in the inlet path are filter elements 41 and 43, the form 400mesh nylon screen which bears against a filter disc 43 preferably ofpolytetrafluoroethylene and in the form of a felt, 10 micron or less inpore size.

As illustrated, the chamber 30, at each end thereof terminates inenlarged end sections 46 and 47, in the form of counter-bores each ofwhich receives a press fitted plug 48 and 49, respectively. Each plugincludes an interior counter-bore, 51, 53, respectively, and a passagetherethrough, as illustrated. On the ends of the plugs facing thechamber 30, the plugs include a diverging conical opening 56, 57, and anannular shoulder which receives an o-ring seal element, as shown, thelatter forming a seal in the respective counter-bored ends of thesupport body 27.

Plug 49 operates to compress filters 41 and 43 in place, the screen 41operating to prevent the felt from entering the conical opening 57.

Attachment to the chamber holder is through the end plugs 48, 49 and theend bores 51, 53 thereof. Thus, the chamber holder is removed as a unitand replaced with a chamber holder for an immunoadsorbent of an antibodyspecific to the antigen being run in that particular assay. When notused, the appropriately identified chamber holder may be stored at 4° C.

Chamber holders as described for supporting immobilized immunoadsorbentshave been used in assays of the various antigens identified. Theimmunoadsorbents of this invention have been used for over 500 assaysfor each immunoadsorbent and still continue to function with resultsfavorable to those obtained with the classical methods, i.e. standarddeviation of between 5% and 6%.

The chamber holder includes a diverging cone 57 in the inlet end to thechamber for the purpose of dispersing the flow over the bed of theparticulate immunoadsorbent in the chamber 30. Diverging opening 56operates as a collector for the material exiting, while plug 46 supportsthe porous plug 34 within the chamber.

While dextran has been described as a useable polymer, the invention isnot limited to that specific material. Other water insoluble polymermaterials with available hydroxy groups for cyanogen bromide activationmay be used, e.g. cellulose and the like. Dextran is preferred, however,because of the considerable use of this material in radioimmunoassay inthe prior art, e.g. dextran coated charcoal, and its behavior in theenvironment is not detrimental to the procedure.

It will be apparent to those skilled in the art that variousmodifications may be made with respect to the subject matter hereindisclosed. For example, the barrier coating may be used to mask othersubstrates where activity of the substrate is a potential problem. Othermodifications, changes and alterations will be apparent from theforegoing description of illustrative forms of the invention withoutdeparting from the scope of the invention as set forth in the appendedclaims.

I claim:
 1. A chamber holder for an immobilized immunoadsorbent whereinsaid chamber holder is used in a radioimmunoassay procedure for accuratedetermination of the amount of an antigen and wherein said chamberholder is repeatedly reused in such a procedure for subsequent assays ofsaid antigens by show of a mixture of radioactive labelled andunlabelled antigen through said chamber holder, followed by astoichiometric release of the portion of said mixture which is bound tosaid immobilized immunoadsorbent; and release of said chamber holder,comprising:means forming a supporting structure; means defining achamber in said supporting structure; an immobilized immunoadsorbentpositioned within said chamber; said immunoadsorbent including asubstrate stable against dehydration and collapse; said substrate havingassociated therewith antibodies for binding a specific antigen; andmeans cooperating with said chamber to support said immobilizedimmunoadsorbent in said chamber.
 2. A chamber holder as set forth inclaim 1 further including means forming an inlet and an outlet forpassage of fluid through said chamber.
 3. A chamber holder as set forthin claim 2 wherein filter means are positioned in said inlet such thatfluid contacts said filter means prior to contact with saidimmunoadsorbent.
 4. A chamber holder as set forth in claim 1 whereinsaid substrate is particulate and composed of beads having an averagediameter in the range of 10 to 500 microns.
 5. A chamber holder as setforth in claim 4 wherein said support means is a porous plug.
 6. Achamber holder as set forth in claim 5 wherein the pores in said plugare smaller than the diameter of said beads.
 7. A chamber holder as setforth in claim 4 wherein said beads include a surface which is porousand a solid core associated with said porous surface, said antibodiesbeing associated with said porous surface.
 8. A chamber holder as setforth in claim 4 wherein a water insoluble polymer is bonded to theouter surface of the beads, and said antibodies being bonded to saidpolymer.
 9. A chamber holder as set forth in claim 4 wherein said beadsinclude a barrier coating to which said antibodies are bonded.
 10. Achamber holder as set forth in claim 7 wherein said substrate includes amass of solid particles each having an outer surface of high surfacearea compared to said core, the outer surface particles being coatedwith a barrier coating, andsaid antibodies being bonded to said barriercoating.
 11. A chamber holder as set forth in claim 10 wherein saidbarrier coating is in water insoluble polymer.
 12. A chamber holder asset forth in claim 11 wherein said polymer is dextran.
 13. A chamberholder as set forth in claim 6 wherein said pores in said plug are 10microns or smaller.
 14. A chamber holder as set forth in claim 2 whereinsaid inlet includes means to disperse the flow of fluid as said fluidenters said chamber.